Positive Results from Interim Analysis of 'GEN-001' Plus avelumab (Bavencio) Phase II Trial
19 May 2023
Phase 2Clinical ResultDrug ApprovalPriority ReviewLicense out/in
SEOUL, South Korea, May 19, 2023. Genome & Company a global leading microbiome therapeutics developer, announced that this phase II trial (NCT05419362) will continue without modifications to move on to the second stage, based on the positive result of the interim analysis.
Using a single-strain bacteria in combination with avelumab (Bavencio) from Merck KGaA, Darmstadt, Germany and Pfizer Inc., it is the first time to show positive antitumor activity per objective response rate (ORR) in Phase II trial.
On the basis of these results and in accordance with the predetermined hypothesis of the interim analysis, Genome & Company highly expect that the evidence for treatment with GEN-001 plus avelumab as a 3rd line of therapy for gastric or gastroesophageal junction cancer (GC/GEJ) will be strongly established.
This is a Phase II study to evaluate the safety and efficacy of GEN-001 plus Avelumab as a ≥3rd line treatment for PD-L1 positive GCPD-L1 positive GC/GEJ patients regardless of prior immune-oncology treatment. Following enrollment of the 21st patient, a pre-planned interim analysis was conducted and results were reviewed by an independent data monitoring committee.
As the observed ORR met the pre-determined criteria together with no safety concerns, the IDMC recommended to continue with the second stage without modifications and enroll additional 21 patients. The detailed results will be presented at an Oncology conference in the second half of 2023. The top-line data of the final analysis from Phase II are expected in the second half of next year.
Professor Jeeyun Lee, the principal investigator of clinical trials from the Hematology and Oncology Division at Samsung Medical Center, stated, "There is a strong unmet medical need to establish 3rd line of therapy for GC/GEJ patients compared with the establishing 1st and 2nd lines of therapy. Hence, the pre-planned interim result of this trial is quite interesting. We continue to enroll patients and look forward to seeing the final analysis of this trial soon."
The CEO of Genome & Company, Pae, Jisoo, stated, "We attach great significance to presenting data-driven results for the first time through Phase II clinical trials on gastric cancer patients using the immuno-oncology microbiome therapeutic 'GEN-001' in combination with avelumab from Merck KGaA, Darmstadt, Germany and Pfizer Inc." and "we intend to obtain phase II clinical data for 'GEN-001' within next year and to discuss a licensing agreement with partners or global big pharmaceutical companies."
SOURCE Genome & Company
Posted: May 2023
Related articles
FDA Approves Bavencio as First-Line Maintenance Treatment for Patients with Locally Advanced or Metastatic Urothelial Carcinoma - June 30, 2020
FDA Approves Bavencio (avelumab) Plus Inlyta (axitinib) Combination for Patients with Advanced Renal Cell Carcinoma - May 14, 2019
FDA Grants Accelerated Approval to Bavencio (avelumab) for Urothelial Carcinoma - May 9, 2017
FDA Approves Bavencio (avelumab) for Metastatic Merkel Cell Carcinoma - March 23, 2017
FDA Accepts the Biologics License Application for Avelumab for the Treatment of Metastatic Urothelial Carcinoma for Priority Review - February 28, 2017
FDA Accepts the BLA for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma for Priority Review - November 29, 2016
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.